Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Top Cited Papers
- 24 March 2015
- journal article
- research article
- Published by Elsevier
- Vol. 385 (9984) , 2272-2279
- https://doi.org/10.1016/s0140-6736(15)60553-0
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Chimpanzee Adenovirus Vector Ebola VaccineNew England Journal of Medicine, 2017
- Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward ProjectionsNew England Journal of Medicine, 2014
- Emergence of Zaire Ebola Virus Disease in GuineaNew England Journal of Medicine, 2014
- mAbs and Ad-Vectored IFN-α Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and SymptomsScience Translational Medicine, 2013
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsVaccine, 2010
- Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccinationJournal of Immunological Methods, 2007
- Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trialsJournal of Immunological Methods, 2007
- Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy VectorsJournal of Clinical Microbiology, 2003
- On the Trail of Ebola and Marburg VirusesScience, 2000
- Marburg and Ebola VirusesPublished by Elsevier ,1996